Vir Biotechnology, Inc. (NASDAQ:VIR) shareholders will have a motive to smile currently, with the analysts producing substantial upgrades to future year’s statutory forecasts. Consensus estimates recommend investors could assume significantly improved statutory revenues and earnings for every share, with the analysts modelling a genuine improvement in small business efficiency. The […]